North America Pharmaceutical Logistics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

North America Pharmaceutical Logistics Market Trends and Insights

Surge in Cell & Gene Therapy Clinical Trials Requiring Ultra-Cold Distribution Infrastructure

Advanced therapy trials are scaling rapidly, prompting investment in storage solutions that keep cellular material stable at temperatures as low as -196 °C. OmniaBio’s 120,000 square-foot facility in Hamilton, Ontario, now the largest of its kind in Canada, signals growing regional capacity for these therapies. The U.S. FDA’s new Platform Technology Designation for CRISPR-based products simplifies validation steps and shortens review cycles, thus raising shipment volumes that must meet stringent chain-of-custody rules. Logistics providers able to offer validated cryogenic fleets, redundant power back-ups and real-time excursion alerts are well placed to win contracts. Partnerships between manufacturers and 3PLs are also expanding to embed capacity in multi-tenant campuses near research clusters. These dynamics elevate the North America pharmaceutical logistics market as a critical enabler of precision medicine scale-up.

Rise of Direct-to-Patient Models in U.S. Specialty Pharmacy Channel

Manufacturers are building proprietary portals that send high-value drugs directly to patient homes, trimming intermediaries and improving adherence. The direct-to-patient healthcare logistics segment is growing alongside telehealth, which handled over 18% of U.S. outpatient visits in 2024. Last-mile couriers equipped with temperature-verified packaging extend reach to rural areas while blockchain audit trails document custody events for DSCSA compliance. Retail chains are retrofitting clinics to support decentralized clinical trials that rely on just-in-time drug delivery. Automated micro-fulfilment centers near metropolitan zones shorten lead times further. As these practices mature they contribute to recurring revenue streams within the North America pharmaceutical logistics market.

Expansion of U.S.–Mexico Near-Shore Fill-Finish Facilities Creating Cross-Border Cold-Chain Flows

Life-science companies are diversifying supply risk by moving sterile fill-finish lines to northern Mexico. The country’s 14 free-trade agreements and new tax rules that allow 89% deductibility on research machinery lower capital barriers. Cross-border truck volumes of temperature-sensitive goods are rising, though congested ports of entry and fragmented Mexican cold-chain regulations can delay hand-offs. The Wilson Center urges stronger regulatory alignment to safeguard product efficacy and patient safety. Demand for bilingual control-tower services and GPS-tagged passive shippers is therefore escalating. Providers that master customs brokerage, redundant route planning and harmonised data standards are likely to capture incremental share in the North America pharmaceutical logistics market.

Canada’s Biologics Manufacturing Incentives Boosting Demand for GMP Warehousing

Federal and provincial programs are subsidising new biomanufacturing campuses, accelerating the need for certified storage and distribution nodes. Canada’s diverse electronic health-record ecosystem improves real-world evidence capture, attracting multinational trials that require qualified logistics partners. Ottawa’s national pharmacare proposal envisions a single agency to negotiate drug prices and coordinate distribution, which may centralise requirements for temperature-controlled depots. Cross-border flows of biologics into U.S. clinical networks also benefit from the USMCA framework. These initiatives raise warehouse utilisation rates and spur robotics adoption, reinforcing growth prospects for the North America pharmaceutical logistics market.

Chronic Driver Shortages Limiting Domestic Road Capacity for Time-Critical Shipments

The American Trucking Associations estimate the shortfall could reach 160,000 drivers by 2030, straining time-definite lanes for healthcare cargo. Manufacturing plants already cite labour gaps at 20.6%, and higher transportation prices in December 2024 marked the steepest rise since April 2022. Driver turnover erodes on-time performance, pushing shippers to use premium air options or build buffer inventories. Potential immigration restrictions could tighten labour pools further. These pressures inflate operating costs and temper the otherwise strong outlook for the North America pharmaceutical logistics market.

High Cost of Dry-Ice & Liquid-Nitrogen Compliance for ≤-70 °C Modalities

Complex handling protocols for ultra-cold cargo raise insurance, packaging and training expenses. Failures across the global cold chain already cost industry USD 35 billion each year, highlighting financial risk. Maersk estimates that cold-chain medicines comprised 35% of total pharmaceutical volumes in 2022, and the share is climbing with next-generation biologics. Dry-ice sublimation plus limits on aircraft cargo mass can force split shipments, doubling freight bills. While IoT telemetry curbs excursion loss, it cannot fully offset high material costs, moderating the growth rate of modalities that rely on extreme temperatures within the North America pharmaceutical logistics market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Service Type: Transportation Dominates Despite Warehousing Acceleration

Transportation captured 71.35% of the North America pharmaceutical logistics market share in 2025, reflecting the centrality of air, road and multimodal services for timely deliveries across a vast region. Domestic truck routes connect more than USD 1.6 trillion in U.S.-Canada-Mexico trade, while Boeing forecasts 4.1% annual expansion in air-cargo traffic driven by e-commerce and high-value goods, including medicines.

Warehousing and storage, though smaller, is set to grow at.5 6.38% CAGR as manufacturers create inventory buffers for critical drugs and as advanced therapies demand controlled environments. Robotic picking systems and automated cold rooms shorten order cycles and raise accuracy, while ISO-certified clean rooms support secondary packaging and kitting. Labour scarcity accelerates capital investment in automation, and value-added services such as late-stage customisation and regulatory support differentiate providers within the North America pharmaceutical logistics industry.

By Mode of Operation: Cold-Chain Logistics Outpaces Traditional Models

Non-cold-chain services remain the larger category at 53.45% of the North America pharmaceutical logistics market size in 2025, serving most oral solids and medical devices. Cold-chain services are forecasted to expand 7.05% annually through 2031 as biologics, vaccines and advanced therapies proliferate.

Lineage Logistics and Americold operate 71% of regional cold-storage facilities, yet new entrants armed with sensor-enabled containers are challenging incumbents. Real-time monitoring improves successful deliveries to above 99% while reducing CO₂ output, enhancing competitiveness. Software that predicts lane-specific risk allows shippers to choose optimal modes, strengthening resilience in the North America pharmaceutical logistics market.

By Product Type: Cell & Gene Therapies Drive Specialized Logistics Demand

Prescription medicines led with a 37.65% share of the North America pharmaceutical logistics market size in 2025. Over-the-counter products, biosimilars and vaccines follow as mature revenue sources that require strict yet standardised handling.

Cell and gene therapies, although nascent, are projected to post a 11.32% CAGR through 2031. Cryogenic storage at -196 °C, specialised courier escorts and point-of-care delivery models set this class apart. Regulatory agencies are piloting decentralised manufacturing to cut transit time, which could shift logistics from central hubs to regional nodes. Top animal-health firms such as Zoetis, Merck Animal Health and Boehringer Ingelheim also rely on livestock vaccine chains that mirror human vaccine requirements, adding diversity to the North America pharmaceutical logistics market.

Geography Analysis

The United States commanded 81.30% of North America pharmaceutical logistics market revenue in 2025, supported by large-scale drug manufacturing clusters, world-class compliance standards and heavy infrastructure spending. Multi-billion-dollar expansions by Eli Lilly, Johnson & Johnson and Amgen in North Carolina illustrate how new production hubs create parallel demand for validated storage and time-critical transportation. DSCSA milestones continue to catalyse technology adoption, with serialization and data-exchange solutions rolling out across wholesalers, dispensers and 3PLs.

Canada contributes a smaller but strategically important slice of the North America pharmaceutical logistics market. Government incentives for biologics plants, a rich real-world evidence ecosystem and the proposed national pharmacare program are harmonising demand for GMP-compliant depots. Cross-border exchanges under USMCA facilitate two-way flows of APIs and finished dose forms. Continued investment in cold-chain corridors through Ontario and Quebec will lift usage of specialised trucking lanes and air-freight charters.

Mexico is the fastest-growing geography, expected to rise 8.03% on a CAGR basis through 2031. Tax breaks on research and manufacturing equipment and proximity to U.S. buyers make near-shoring attractive. Yet power reliability, water scarcity and cargo security remain hurdles. Strengthened customs coordination and the 2026 USMCA review could further streamline trade, positioning Mexico as a vital node in the broader North America pharmaceutical logistics market.

Regulatory Landscape

In the United States, compliance requirements for pharmaceutical traceability and import controls continue to shape logistics execution. The FDA-administered Drug Supply Chain Security Act (DSCSA) remains the central framework for interoperable, electronic package-level tracing among trading partners. FDA guidance and waiver pathways support implementation beyond the stabilization period and add a compliance runway for certain downstream participants, including a DSCSA milestone extending to November 27, 2026 for small dispensers. Separately, FDA border processes have tightened data expectations for inbound shipments, reflected in updates to the FDA Supplemental Guide for the Automated Commercial Environment (ACE) in March 2026 that clarified required import submission elements for specific pharmaceutical commodities.

Trade and cross-border planning has also been influenced by U.S. policy actions tied to pharmaceuticals and ingredients. A White House presidential action in April 2026 referenced adjustments to imports of pharmaceutical products and pharmaceutical ingredients into the United States under Section 232 authorities, which increases the importance of customs strategy, documentation quality, and network design choices, including use of Foreign Trade Zones and bonded handling, for logistics providers supporting manufacturers, wholesalers, and specialty supply chains. In Canada, Health Canada oversight under the Food and Drug Regulations anchors storage and transportation expectations through GMP-linked requirements, including temperature control guidance (GUI-0069) and mandatory drug shortage and discontinuation reporting managed via Drug Shortages Canada, which raises recordkeeping, lane qualification, and exception management expectations for third-party logistics partners.

Value Chain Analysis

The value chain covers API and finished-dose manufacturers, packaging and labeling providers, and regulated distribution through wholesale and specialty channels. Logistics operators then deliver compliant transportation, warehousing, and value-added services that connect these upstream and downstream steps. In North America, the execution layer is dominated by global integrators (DHL, UPS, FedEx) and specialist providers focused on clinical and ultra-cold movements, including CryoPDP and Marken, alongside regional healthcare distributors and 3PLs with GMP/cGDP capabilities in the United States and Canada.

Service flows typically move from plant gate to validated storage (ambient and multi-temperature), then into line-haul (road, air, and multimodal) and onward to licensed healthcare wholesalers and hospitals. Increasingly, operators rely on control towers, serialization data exchange, and real-time temperature telemetry to meet DSCSA and GMP expectations. Key enabling inputs include qualified packaging (passive and active), dry ice and cryogenic handling capability for advanced therapies, calibrated monitoring devices, and trained labor for GDP/GMP operations. Bottlenecks noted across the chain include limited time-definite road capacity during labor shortages, weather and infrastructure disruptions that undermine just-in-time replenishment models, and border congestion and regulatory fragmentation that complicate U.S.-Mexico handoffs for temperature-sensitive cargo. Policy-related cost shocks, such as changes in U.S. import measures affecting pharmaceuticals and ingredients, add complexity in landed-cost management and inventory positioning, pushing some shippers toward Foreign Trade Zones and bonded workflows, and encouraging more deliberate network redundancy for high-value and temperature-controlled product categories.

Market Opportunities and Future Outlook

Cold-chain capacity build-out and automation-led compliance are emerging as clear whitespace areas, supported by measurable investments in 2025-2026. UPS Healthcare announced a USD 48 million investment (June 2026) spanning 27 temperature-controlled cross-dock facilities to support multiple temperature bands (2-8 C, 15-25 C, and frozen), reflecting rising throughput needs for biologics and injectable therapies that depend on fast transfer points and strict excursion control. In distribution infrastructure, McKesson disclosed a USD 179 million automated regional distribution center project in Moore, Oklahoma (June 2026) with expanded cold-chain capability and standby power, pointing to ongoing demand for resilient, high-uptime nodes that can sustain service levels during grid events and peak demand cycles.

Opportunities also center on airport-adjacent pharma-grade storage, domestic repositioning of inventory to manage trade friction, and higher-value services that sit between warehousing and transport. Langham Logistics opened a large pharmaceutical cold-chain facility in Plainfield, Indiana (June 2026) near Indianapolis International Airport with substantial refrigerated pallet positions, which highlights demand for rapid air-road handoffs and validated dwell time in multi-tenant environments. On the service side, DSCSA-driven interoperability and Canada’s GMP temperature-control expectations expand the need for serialization-ready distribution, exception management, and audit-ready data capture, benefiting providers that can integrate WMS/TMS with tracing and monitoring systems. Network strategies that incorporate Foreign Trade Zones and bonded handling are being used to improve duty and cash-flow management in response to shifting U.S. import measures affecting pharmaceuticals and ingredients, adding demand for brokers, FTZ operators, and control-tower orchestration across the United States, Canada, and Mexico corridors.